Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ASH18

- PMLiVE

Amgen and Synaffix sign licensing agreement worth up to $2bn

Amgen will gain access to Synaffix' proprietary antibody-drug conjugates technologies

- PMLiVE

Sanofi and Innate Pharma expand cancer therapeutics collaboration

The partnership is aimed at exploring the potential of natural killer cells therapeutics in oncology

- PMLiVE

ICR twin study indicates childhood leukaemia begins in the womb

The study, published in Leukemia, will help clinicians advise parents of twins with ALL

- PMLiVE

iOnctura awarded €17.5m from EIC Accelerator for novel pancreatic cancer therapy

The company dosed the first patient in a phase 1b study of IOA-289 earlier this month

- PMLiVE

Novartis receives EC approval for Pluvicto to treat adult cancer patients

Patients receiving Pluvicto plus best standard of care had a 38% reduction in the risk of death

- PMLiVE

Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022

The acquisition will see Amgen pay $116.50 for each Horizon share in cash

- PMLiVE

Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study

The data was shared during the 2022 American Society of Hematology Annual Meeting

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

- PMLiVE

Pfizer shares updated pivotal phase 2 elranatamab data for multiple myeloma

There are 176,000 new cases of the disease worldwide for which there is currently no cure

- PMLiVE

Kite and Arcellx partner to develop and commercialise multiple myeloma candidate

Arcellx is set to receive an upfront cash payment of $225m and $100m equity investment

- PMLiVE

Gilead announces positive new data for Trodelvy in metastatic breast cancer

The treatment demonstrated consistent efficacy across Trop-2 expression levels

- PMLiVE

Lilly shares positive Verzenio data as adjuvant early breast cancer therapy

Results were shared in The Lancet Oncology and at the San Antonio Breast Cancer Symposium

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links